The Lancet Covers Altasciences’ Contribution to Research for Weight Management
A Look into Weight Management Research
Altasciences’ Medical Director and Investigator, Dr. Martin Kankam, M.D., PhD, MPH, along with a team of scientific experts, have successfully investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2•4 mg for weight management, in a randomized, controlled, Phase Ib trial.
Access the full article co-authored by Dr. Kankam to learn about the findings, methods, and results of this trial.
As experts in the field, we have conducted over 75 early stage trials involving antidiabetic and hypoglycemic agents in patients who are diabetic (Type 1 and 2), obese, or have metabolic syndrome or NASH. These include a large number of proof-of-concept studies investigating different measures of glucose tolerance, including clamping studies using the state-of-the-art YSI 2950D biochemistry analyzer to efficiently process multiple glucose samples per run.
Speak with a metabolic disorder expert today.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
You may also be interested in:
- The Altascientist: The Global Challenge of Metabolic Disorders
- Fact Sheet: First-in-Human Capabilities
- Webpage: Proof-of-Concept Capabilities
- Press Release: Altasciences Qualifies Quantitative Serological Assay for the Detection of SARS-CoV-2 IgG Antibodies
- Press Release: WCCT Global (an Altasciences Company) Clinic Expansion